Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19

One of Novartis’ top late-stage candidates for multiple sclerosis is now under review on both sides of the Atlantic.

Having stoked enthusiasm for siponimod through a solid Phase III data package, the Swiss drugmaker traded in a priority review voucher at the FDA for an expedited action date around March of next year. The EMA decision, meanwhile, will likely come in late 2019.